Answers are grounded in this paper and cite their sources.
This letter reports two cases of severe demyelinating polyradiculoneuropathy after treatment with pembrolizumab, a humanized antibody against programmed cell death 1 receptor, for advanced melanoma.
No takes yet. Share an insight, caveat, or question.
Maleissye et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: